Biodexa Pharmaceuticals (BDRX) Total Current Liabilities (2013 - 2025)

Biodexa Pharmaceuticals has reported Total Current Liabilities for 13 years, with the latest figure at $8.2 million in Q4 2025.

• Quarterly Total Current Liabilities rose 26.18% year-over-year to $8.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.2 million (up 26.18% YoY) and the FY2025 annual result came in at $8.1 million, up 25.07% from the prior year.
• Total Current Liabilities climbed to $8.2 million in Q4 2025 per BDRX's latest filing, from $3.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $8.2 million in Q4 2025 and troughed at $2.1 million in Q2 2022.
• A 5-year average of $4.4 million and a median of $3.9 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities tumbled 61.41% in 2022, then surged 210.15% in 2023.
• Over 5 years, Total Current Liabilities stood at $2.5 million in 2021, then dropped by 10.2% to $2.2 million in 2022, then soared by 210.15% to $6.9 million in 2023, then retreated by 6.52% to $6.5 million in 2024, then increased by 26.18% to $8.2 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $8.2 million, $3.3 million, and $6.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.